Federico de la Rosa
Research Institute Hospital 12 de Octubre · 89 works · 992 citations · h-index 14
Top works
- Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.
- BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer
- UroMark—a urinary biomarker assay for the detection of bladder cancer
- Kidney transplant from uncontrolled donation after circulatory death donors maintained by nECMO has long-term outcomes comparable to standard criteria donation after brain death
- In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
- Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer
- PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
- CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
- Donation after cardiac death: results of the SUMMA 112 – H ospital 12 de O ctubre P rogram
- A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
- Primary Cisplatin, Methotrexate and Vinblastine Chemotherapy With Selective Bladder Preservation for Muscle Invasive Carcinoma of the Bladder: Long-Term Followup of a Prospective Study
- Urological Complications After Simultaneous Pancreas-Kidney Transplantation
- Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer
- BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up
- Tratamiento de la trombosis de vena cava inferior asociada a los tumores renales
- Atezolizumab + intravesical BCG (Bacillus Calmette-Guerin) in high-risk non-muscle invasive bladder cancer (NMIBC) patients: Institutional clinical and translational study (BladderGATE).
- Treatment of Caval Vein Thrombosis Associated With Renal Tumors
- Prospective exploratory analysis of the association between genetic polymorphisms and sunitinib toxicity and efficacy in metastatic renal-cell carcinoma.
- Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in high risk non–muscle- invasive bladder cancer (NMIBC) patients: Safety interim report of BladderGATE phase I-II study.
- Analysis of molecular profiling of renal cell carcinoma: Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II disease.